title: Inter occasion variability in individual optimal design.
abstract: Inter occasion variability (IOV) is of importance to consider in the development of a design where individual pharmacokinetic or pharmacodynamic parameters are of interest. IOV may adversely affect the precision of maximum a posteriori (MAP) estimated individual parameters, yet the influence of inclusion of IOV in optimal design for estimation of individual parameters has not been investigated. In this work two methods of including IOV in the maximum a posteriori Fisher information matrix (FIMMAP) are evaluated: (i) MAP occ-the IOV is included as a fixed effect deviation per occasion and individual, and (ii) POP occ-the IOV is included as an occasion random effect. Sparse sampling schedules were designed for two test models and compared to a scenario where IOV is ignored, either by omitting known IOV (Omit) or by mimicking a situation where unknown IOV has inflated the IIV (Inflate). Accounting for IOV in the FIMMAP markedly affected the designs compared to ignoring IOV and, as evaluated by stochastic simulation and estimation, resulted in superior precision in the individual parameters. In addition MAPocc and POP occ accurately predicted precision and shrinkage. For the investigated designs, the MAP occ method was on average slightly superior to POP occ and was less computationally intensive.
authors.affiliation: Department of Pharmaceutical Biosciences, Uppsala University, Box 591, 75124, Uppsala, Sweden. Anders.Kristoffersson@farmbio.uu.se.
authors.forename: Anders N
authors.identifier: http://orcid.org/0000-0003-3166-9981
authors.initials: AN
authors.lastname: Kristoffersson
authors.affiliation: Department of Pharmaceutical Biosciences, Uppsala University, Box 591, 75124, Uppsala, Sweden.
authors.forename: Lena E
authors.initials: LE
authors.lastname: Friberg
authors.affiliation: Department of Pharmaceutical Biosciences, Uppsala University, Box 591, 75124, Uppsala, Sweden.
authors.forename: Joakim
authors.initials: J
authors.lastname: Nyberg
mesh_terms: D000818:Animals; D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000493:pharmacokinetics*; D001499:Bayes Theorem; D001711:Biotransformation; D003091:Colistin / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000493:pharmacokinetics; D003627:Data Interpretation, Statistical; D004334:Drug Administration Schedule; D006801:Humans; D008954:Models, Biological; D015233:Models, Statistical; D011355:Prodrugs / Q000008:administration & dosage / Q000493:pharmacokinetics*; D015203:Reproducibility of Results; D012107:Research Design / Q000706:statistics & numerical data*; D014018:Tissue Distribution
chemical_list: D000900:Anti-Bacterial Agents; D011355:Prodrugs; C004691:colistinmethanesulfonic acid; D003091:Colistin
keywords: Bayesian; Fisher information; Inter occasion variability (IOV); Maximum a posteriori (MAP); Optimal design (OD); Pharmacometrics; Shrinkage